netbiz

About netbiz

This author has not yet filled in any details.
So far netbiz has created 34 blog entries.

Orsense Ltd.

OrSense Receives FDA Clearance for its Noninvasive Hemoglobin Monitor
etach Tikva, Israel, November 5, 2013 – OrSense Ltd., developer of solutions for non-invasive measurements of various blood parameters, today announced that it has received FDA clearance for its NBM-200MP, noninvasive hemoglobin (Hb) and pulse oximetry monitor. NBM-200MP belongs to OrSense’s NBM-200 family of products, for the

Orsense Ltd.

OrSense Non Invasive Hemoglobin Monitor Received CFDA Approval for Marketing in China
Petach Tikva, Israel, October 28, 2013 – OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, today announced that it has received China Food and Drug Administration approval for NBM-200, its non-invasive hemoglobin (Hb) system for anemia monitoring and hemorrhage detection.

Gamida Cell Ltd.

 Gamida Cell Announces the Successful Transplantation of the First Patient in The Company’s Phase I/II Study of NiCord® in a Single Cord Configuration
We are witnessing a paradigm shift in transplantation. The first patient was successfully transplanted with a stem cell graft entirely expanded in ex vivo cultures and without the support of a second unit

Orsense Ltd.

OrSense Non Invasive Hemoglobin Monitor Shown Safe and Accurate for Pre-Donation Screening in Blood Banks
OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced today that its non-invasive Hemoglobin (Hb) NBM-200 monitor was the topic of multiple recent studies highlighting the clinical value of the device. Four studies, from various countries around

NanoPass Technologies Ltd.

NanoPass Technologies Supports a CDC-Sponsored Phase 3 Study of Polio Vaccine in Infants as Part of its Global Health Initiative
NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal (into-the-skin or ID) vaccine delivery solutions, is collaborating with the US Center of Disease Control and prevention (CDC) in conducting a large phase 3 trial of polio vaccine

Gamida Cell Ltd.

Gamida Cell Reports StemEx® Phase II/III Study Safety and Efficacy Data
Jerusalem, Israel, — Gamida Cell announced today additional analyses for the Phase II/III, multi-center, multi-national, historical cohort-controlled study to evaluate efficacy and safety of StemEx® as an alternative transplantation treatment for patients with high risk leukemia and lymphoma. Twenty-five bone marrow transplant centers worldwide treating

NanoPass Technologies Ltd.

IDRI and Medicago to present data at the World Vaccine Congress Presentation of Positive Interim Phase I Clinical Trial results for an H5N1 Vaccine with GLA Adjuvant
SEATTLE, WA, and QUEBEC CITY, QC, April 9, 2013 – IDRI (Infectious Disease Research Institute), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in

Argo Medical Technologies Ltd.

President Obama Views Demonstration of ReWalk Exoskeleton Technology During Visit to Israel
ARGO Medical Technologies’ ReWalk exoskeleton was one of the cutting-edge Israeli inventions demonstrated to President Barack Obama in Israel during his visit to a session hosted by Technion-Israel Institute of Technology. ReWalk inventor Dr. Amit Goffer an alumni of the Technion is a quadriplegic

Gamida Cell Ltd.

Gamida Cell’s StemEx® Achieves Primary Endpoint in Phase II/III Clinical Study
Jerusalem, Israel – Gamida Cell announced today that its flagship product, StemEx, reached its primary endpoint of improving overall survival in a Phase II/III study which compared the use of StemEx as part of a transplantation regimen to historical controls in the treatment of patients

Argo Medical Technologies Ltd.

ARGO Medical Technologies Unveils Advancement of its Exoskeleton Technology with Launch of ReWalk Rehabilitation 2.0
BERLIN, Jan 29, 2013 (BUSINESS WIRE) — ARGO Medical Technologies has unveiled the newest generation of its ReWalk Rehabilitation exoskeleton that enables individuals with spinal cord injuries the ability to walk again. The 2.0 system is designed to make it easier